FULVESTRANT

Clinical Indication

Oestrogen receptor positive metastatic or locally advanced breast cancer in post menopausal women in whom disease progresses or relapses while on or after other anti oestrogen therapy

Comments

Secondary care will administer first three doses.

Date of classification

May 2015

Review date

May 2015

Amber SIMPLE

Drugs suitable to be initiated and prescribed in primary care only after specialist assessment and recommendation. A shared care agreement is not required.